stockrowRegeneron Pharmaceuticals, Inc.
REGN Healthcare Biotechnology
Regeneron Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.3 billion, up 0.99% from fiscal 2024.
- Revenue
- +36.3%
- EPS
- +36.0%
- Free cash flow
- +3.85%
- Total debt
- −26.6%
Quarter to September 2026, against a year earlier
Follow REGN
Alert me
Regeneron Pharmaceuticals, Inc. (REGN) Total debt
Regeneron Pharmaceuticals, Inc.'s total debt at the end of fiscal 2025 was $2.7B, unchanged from fiscal 2024. At the end of the quarter to 30 September 2026 it was $2.0B. Over the past ten years it has ranged from $351.6M (fiscal 2016) to $2.7B (fiscal 2025) — the current reading is the highest in ten years. Regeneron Pharmaceuticals, Inc. ranks 8th of 569 Biotechnology companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2025 | $2.7B | 0.06% |
| FY2024 | $2.7B | 0.06% |
| FY2023 | $2.7B | 0.06% |
| FY2022 | $2.7B | 36.43% |
| FY2021 | $2.0B | (26.55%) |
| FY2020 | $2.7B | 277.60% |
| FY2019 | $713.9M | 0.76% |
| FY2018 | $708.5M | 0.71% |
| FY2017 | $703.5M | 100.10% |
| FY2016 | $351.6M | (3.13%) |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Sep 2026 | $2.0B | 0.02% |
| Jun 2026 | $2.0B | 0.02% |
| Mar 2026 | $2.0B | (26.60%) |
| Dec 2025 | $2.7B | 0.01% |
| 43 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| RPRX Royalty Pharma PLC compare | $8.6B |
| GMAB Genmab A/S Sponsored ADR compare | $5.1B |
| VRTX Vertex Pharmaceuticals Incorporated compare | $3.5B |
| REGN Regeneron Pharmaceuticals, Inc. | $2.0B |
| RVMD Revolution Medicines, Inc. compare | $1.0B |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | $825.2M |
| MRNA Moderna, Inc. compare | $597.0M |
| ROIV Roivant Sciences Ltd. compare | $323.7M |
| ARGX argenex SE compare | $7.6M |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on REGN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement